As an inhibitor of high mobility group box 1 (HMGB1), a pro-inflammatory protein, GA shows therapeutic potential in HMGB1-mediated conditions such as traumatic brain injury, neuroinflammation, seizures, Alzheimer’s disease, multiple sclerosis and PD [10]. This evidence concerns the gene HMGB1 and early-onset autosomal dominant Alzheimer disease.